Literature DB >> 27146861

Remission and withdrawal of therapy in lupus nephritis.

Gabriella Moroni1, Francesca Raffiotta2, Claudio Ponticelli2,3.   

Abstract

There is agreement that early diagnosis and aggressive treatment of lupus nephritis exacerbations are of paramount importance to achieve remission and prevent the development of irreversible lesions. There is less agreement about the optimal duration of maintenance treatment. Instead, the prolonged exposure to corticosteroids and/or immunosuppressive drugs can cause invalidating or even life-threatening complications. It is still unclear if these drugs can be safely withdrawn in lupus patients. We were able to completely withdraw therapy in around 1/3 of our patients after a follow-up of 5 years or more; 60 % of them never had to start therapy again. Based on our own experience, discontinuation of therapy should be applied only in selected cases, i.e. patients who received maintenance therapy for at least 5 years and are in complete renal remission for at least 3 years. Antimalarial agents are helpful in maintaining the remission after withdrawal of therapy. However, to achieve these goals, drugs should be tapered off very slowly and under strict surveillance. If all these prerequisites are satisfied, the withdrawal of therapy in patients with lupus nephritis may be considered safe, may improve the patients' quality of life and may reduce the damage accrual.

Entities:  

Keywords:  Corticosteroids; Immunosuppressive agents; Lupus nephritis; Remission; Withdrawal of therapy

Mesh:

Substances:

Year:  2016        PMID: 27146861     DOI: 10.1007/s40620-016-0313-6

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  41 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide.

Authors:  J P Ioannidis; K A Boki; M E Katsorida; A A Drosos; F N Skopouli; J N Boletis; H M Moutsopoulos
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

3.  Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy.

Authors:  E Sharon; D Kaplan; H S Diamond
Journal:  N Engl J Med       Date:  1973-01-18       Impact factor: 91.245

4.  Exacerbation of SLE nephritis after cyclophosphamide withdrawal.

Authors:  R G Aptekar; J L Decker; A D Steinberg
Journal:  N Engl J Med       Date:  1972-05-25       Impact factor: 91.245

Review 5.  Clinical presentation and monitoring of lupus nephritis.

Authors:  J E Balow
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

7.  Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.

Authors:  Gabriella Moroni; Beniamina Gallelli; Silvana Quaglini; Giovanni Banfi; Emilio Rivolta; Piergiorgio Messa; Claudio Ponticelli
Journal:  Nephrol Dial Transplant       Date:  2006-02-02       Impact factor: 5.992

8.  Induction and maintenance therapy in proliferative lupus nephritis.

Authors:  Claudio Ponticelli; Richard J Glassock; Gabriella Moroni
Journal:  J Nephrol       Date:  2010 Jan-Feb       Impact factor: 3.902

9.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Authors:  F A Houssiau; C Vasconcelos; D D'Cruz; G D Sebastiani; E de Ramon Garrido; M G Danieli; D Abramovicz; D Blockmans; A Cauli; H Direskeneli; M Galeazzi; A Gül; Y Levy; P Petera; R Popovic; R Petrovic; R A Sinico; R Cattaneo; J Font; G Depresseux; J-P Cosyns; R Cervera
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

10.  Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.

Authors:  Farah Tamirou; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Christoph Fiehn; Maria del Mar Ayala Guttierez; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera; Frédéric A Houssiau
Journal:  Ann Rheum Dis       Date:  2015-03-10       Impact factor: 19.103

View more
  5 in total

1.  Regulation of MiR-146a and TRAF6 in the Diagnose of Lupus Nephritis.

Authors:  Yunfeng Zhu; Zhenzhen Xue; Lizhe Di
Journal:  Med Sci Monit       Date:  2017-05-26

2.  Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis.

Authors:  Haijun Ma; Chang Liu; Bingyu Shi; Zhuoya Zhang; Ruihai Feng; Minghao Guo; Liwei Lu; Songtao Shi; Xiang Gao; Wanjun Chen; Lingyun Sun
Journal:  EBioMedicine       Date:  2018-06-07       Impact factor: 8.143

3.  Diagnostic performance of serum cystatin C and complement component 1q in lupus nephritis.

Authors:  Bei Xu; Ya-Mei Zhang; Yu-Wei Yang; Yun-Shuang Liu; Jia-Fu Feng
Journal:  Arthritis Res Ther       Date:  2019-12-04       Impact factor: 5.156

Review 4.  Treatment of Lupus Nephritis from Iranian Traditional Medicine and Modern Medicine Points of View: A Comparative Study.

Authors:  Yasaman Vahedi-Mazdabadi; Mina Saeedi
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-09       Impact factor: 2.629

Review 5.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.